MDNC 8-K
Medinotec Inc. (MDNC)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
|
North Riding | |
|
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
|
________________________________________________ (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On March 21, 2023, Medinotec, Inc. (the “Company”) was notified by FINRA’s Department of Market Operations that the Company’s common stock may be traded in the market for unlisted securities (i.e., the “over-the-counter market”) under the symbol “MDNC”. The change in ticker symbol did not result in a change to the CUSIP number for the Company’s common stock. The Company issued a press release, which is furnished with this Current Report on Form 8-K as Exhibit 99.1.
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit No. | Description |
| 99.1 | Press Release, dated March 21, 2023 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Medinotec Inc.
/s/ Pieter van Niekerk
Pieter van Niekerk
Chief Financial Officer
Date: March 21, 2023
| 3 |
MEDINOTEC, INC. ANNOUNCES Assignment of an Over-the-Counter Quoting and Trading Symbol (MDNC) for the Common Stock of Medinotec Inc.
Las Vegas, NV – March 21, 2023 -- Medinotec, Inc. (the “Company”) (OTCPink: MDNC), a US-based company with a primary investment in DISA Medinotec, a South African medical device manufacturing and distribution company, in managements opinion a global leader in tracheal non-occlusive airway dilation technology and medical device design, manufacture and distribution, today announced the Company was notified by FINRA’s Department of Market Operations that the Company’s common stock may be traded in the market for unlisted securities (i.e., the “over-the-counter market”) under the symbol “MDNC,” effective at the opening of trading hours on Tuesday, March 21, 2023. The change in ticker symbol did not result in a change to the CUSIP number for the Company’s common stock. The Company intends to upgrade to the OTCQX tier of OTC Markets. There is no assurances, however, that the Company will meet the requirements to do such.
MEDINOTEC Inc. (https://www.medinotecinc.com/) is a US-based company with a primary investment in DISA Medinotec (“Medinotec”), a South African medical device manufacturing and distribution company, This company is in managements opinion a global leader in tracheal non-occlusive airway dilation technology and medical device design, manufacturing and distribution. Medinotec Inc. is seeking to expand sales and distribution operations and networks into the US market, with plans to obtain a quotation on the OTCQX markets in the near future.
In 2018 Medinotec developed its most innovative product to date – the Trachealator. This award-winning balloon catheter was developed to address an as-yet unmet global need in the specialty of advanced airway management, more specifically non-occlusive tracheal dilation. This product has the ability to dilate a patient’s airway while maintaining ventilation to the patient without obstructing his/her airway.
Safe Harbor Statement: Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and MEDINOTEC Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Investor Contact:
Deborah Chapman or
Vanessa Rech
+27 76 650 4155 or +27 83 307 5600
[email protected] or [email protected]
Source: Medinotec